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Abstract 25 
A simple, sensitive and specific high-performance liquid chromatography method for 26 
the quantification of bisnaphthalimidopropyldiaminoctane (BNIPDaoct), a potent anti-27 
Leishmania compound, incorporated into poly(D,L-lactide-co-glycolic acid) (PLGA) 28 
nanoparticles was developed and validated towards bioanalysis application. Biological 29 
tissue extracts were injected into a reversed-phase monolithic column coupled to a 30 
fluorimetric detector (λexc = 234 nm, λemis = 394 nm), using isocratic elution with 31 
aqueous buffer (acetic acid/acetate 0.10 mol L-1, pH 4.5, 0.010 mol L-1 octanesulfonic 32 
acid) and acetonitrile, 60:40 (v/v) at a flow rate of 1.5 mL min-1. The run time was 6 33 
min, with a BNIPDaoct retention time of 3.3 min. 34 
Calibration curves were linear for BNIPDaoct concentrations ranging from 0.002 to 35 
0.100 µmol L-1. Matrix effects were observed and calibration curves were performed 36 
using the different organ (spleen, liver, kidney, heart and lung) extracts. The method 37 
was found to be specific, accurate (97.3-106.8% of nominal values) and precise for 38 
intra-day (RSD < 1.9%) and inter-day assays (RSD < 7.2%) in all matrices. Stability 39 
studies showed that BNIPDaoct was stable in all matrices after standing for 24 h at 40 
room temperature (20 °C) or in the autosampler, and after three freeze/thaw cycles. 41 
Mean recoveries of BNIPDaoct spiked in mice organs were > 88.4%. The LOD and 42 
LOQ for biological matrices were ≤ 0.8 and ≤ 1.8 nmol L-1, respectively, corresponding 43 
to values ≤ 4 and ≤ 9 nmol g-1 in mice organs. The method developed was successfully 44 
applied to biodistribution assessment following intravenous administration of 45 
BNIPDaoct in solution or incorporated in PLGA nanoparticles. 46 
 47 
Keywords: Poly(D,L-lactide-co-glycolic acid); Bisnaphthalimidopropyldiaminooctane; 48 
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1. Introduction 51 
Naphthalimides and bisnaphthalimides are cytotoxic DNA-intercalating compounds, 52 
with well-established activity against several cancers [1]. Bisnaphthalimidopropyl 53 
derivatives (BNIPs) linked to natural polyamines were designed and synthesized to 54 
exhibit good cytotoxicity against cancer cells and parasites [2-7]. In particular, 55 
bisnaphthalimidopropyldiaminooctane (BNIPDaoct, Fig. 1) was shown to exert 56 
promising activity against certain cancer cells (pancreas, breast and leukaemia) and 57 
Leishmania infantum protozoa, eliciting cell death by apoptosis with DNA damage [4, 58 
8, 9]. However the lack of aqueous solubility and some toxic effects to normal cell at 59 
higher doses has made BNIPDaoct in vivo testing difficult and highly limited [4]. To 60 
overcome these problems, BNIPDaoct was incorporated into polymeric nanoparticles of 61 
poly(lactic-co-glycolic) acid (PLGA), a biodegradable and biocompatible polymer 62 
approved by Food Drug Administration for therapeutic applications. By applying such a 63 
drug delivery system one can reduce compound cytotoxic activity side effects, increase 64 
their aqueous solubility properties and alter compound pharmacokinetics profile [10]. In 65 
a previous report, it was demonstrated that PLGA nanoparticles provided controlled and 66 
effective delivery of BNIPDaoct for treatment of visceral leishmaniasis caused by 67 
Leishmania infantum protozoa [11]. In this respect it has emerged a need for rapid, 68 
sensitive and reliable analytical method that can be used to accurately quantify 69 
BNIPDaoct in biological samples. 70 
             71 
Figure 1. Chemical structure of BNIPDaoct 72 
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Concerning the analytical determination of bisnaphthalimides, reports are scarce. A 73 
validated method for the determination of bisnafide in human plasma by HPLC with 74 
UV detection has been described, requiring extensive sample treatment, involving 75 
removal of sample proteins, pH adjustment, extraction to ethyl ether followed by back-76 
extraction to phosphoric acid aqueous solution [12]. In fact, fluorescent properties of 77 
bisnaphthalimides [13, 14] have been applied for monitoring their binding to 78 
biomolecules [15], but their application in validated analytical methods have not been 79 
described yet. 80 
In this context, HPLC coupled to fluorometric detection is a suitable tool to bioanalysis 81 
of nanoparticles loaded with bioactive compounds. In fact, C18 monolithic columns, 82 
consisting of micro- and mesopores [16, 17], have been shown as suitable alternatives 83 
for bioanalysis [18, 19], fostering minimal sample treatment. Hence, the objective of the 84 
present work was the development and validation of HPLC method based on monolithic 85 
column for determination of BNIPDaoct in biological samples, targeting the evaluation 86 
of its biodistribution as free compound or loaded in nanoparticles. 87 
 88 
2. Experimental 89 
2.1. Chemicals 90 
Sodium acetate and octanesulfonic acid were purchased from Sigma-Aldrich (St Louis, 91 
MO, USA). Acetonitrile (LiChrosolv HPLC grade), dimethyl sulfoxide (DMSO) and 92 
acetic acid were obtained from Merck (Darmstadt, Germany). Water from Arium water 93 
purification system (resistivity > 18 MΩ cm, Sartorius, Goettingen, Germany) was used 94 
for the preparation of solutions. Aqueous buffer (acetic acid/acetate 0.10 mol L-1, pH 95 
4.5, 0.010 mol L-1 octanesulfonic acid) was filtered through a 0.22 μm Millipore GVWP 96 
filter. Prior to use, the mobile phase was degassed in an ultrasonic bath for 15 min. 97 
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PLGA (lactide:glycolide [65:35], molecular weight: 40,000-75,000 Da) and poly(vinyl 98 
alcohol) (PVA; 87-89% hydrolyzed, molecular weight: 13,000-23,000 Da) were 99 
acquired from Sigma-Aldrich. BNIPDaoct, represented in Fig. S1, was synthesized as 100 
described previously [4]. 101 
2.2. Preparation and characterization of PLGA nanoparticles containing BNIPDaoct 102 
The biodegradable and biocompatible PLGA was chosen for the production of the 103 
nanoparticles by a nanoprecipitation method described in detail elsewhere [11]. Briefly, 104 
the polymer was dissolved in acetone at ~10 mg mL-1 to form the diffusing phase. 105 
BNIPDaoct in DMSO was then added to reach 10% drug loading (w/w). This phase 106 
(c.a. 1 mL) was added to the PVA 1% (w/v) dispersing phase (10–15 mL) and the 107 
organic solvent was evaporated overnight, at room temperature. The formed 108 
nanoparticles were then recovered and washed by centrifugation, resuspended in 109 
phosphate buffered saline (PBS) at pH 7.4. Unloaded PLGA nanoparticles were also 110 
prepared, using the same procedure without the addition of compound. 111 
Particle size and distribution (polydispersity index, PI) were determined by dynamic 112 
light scattering (DLS), using a Zetasizer Nano ZS laser scattering device (Malvern 113 
Instruments Ltd., Malvern, UK) as described elsewhere [11]. Their mean size was 156 ± 114 
3 nm, with a polydispersity index of 0.08 ± 0.03, and Zeta potential of -5.1 ± 0.7 mV. 115 
2.3. Chromatographic analysis 116 
2.3.1. Equipment and analytical conditions 117 
Samples were injected (20 μL) into a reversed-phase monolithic column (Chromolith 118 
RP-18e, 100 mm × 4.6 mm i.d., Merck), connected to a Jasco (Easton, USA) HPLC 119 
system (pump PU-2089, autosampler AS-2057 and LC-Net II/ADC controller) coupled 120 
to a fluorimetric detector (Jasco FP-2020, λexc = 234 nm, λem = 394 nm). The 121 
chromatographic separation was achieved by isocratic mode using a mobile phase 122 
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consisting of aqueous buffer (acetic acid/acetate 0.10 mol L-1, pH 4.5, 0.010 mol L-1 123 
octanesulfonic acid)-acetonitrile (60:40, v/v) at a flow rate of 1.5 mL min-1. 124 
2.3.2. Preparation of stock and standard solutions 125 
Stock solutions of BNIPDaoct were prepared daily in mobile phase at 20 µmol L-1, 126 
followed by intermediate dilution to 1 µmol L-1. Working standards were prepared from 127 
1 µmol L-1 intermediate stock solution, ranging from 2 to 100 nmol L-1. QC samples at 128 
three different levels (low, middle and high) were prepared (6, 20 and 100 nmol L-1) in 129 
mobile phase from the intermediate stock solution. 130 
2.3.3. Preparation of biological matrices samples 131 
Firstly, methanol was added to each organ at 1:2 (w/v, g/mL) for kidney, liver, and lung 132 
or at 1:5 (w/v, g/mL) for heart and spleen, following homogenization using a high-133 
intensity IKA ultra-turrax. Next, the homogenates were dried under N2 and then they 134 
were reconstituted using mobile phase (1:5, w/v, g/mL). This mixture was vigorously 135 
vortexed for 30 s, followed by sonication during 1 min, and then vortexed again for 30 136 
s. The extract obtained was filtered (PVDF, 0.22 µM) and analyzed for BNIPDaoct 137 
content by HPLC. QC samples were also prepared using the extract, as described in 138 
section 2.3.2. 139 
2.4. Method validation 140 
The chromatographic method was validated for specificity, linearity, accuracy, 141 
precision, range and robustness in accordance with EMA and ICH guidelines [20, 21]. 142 
2.4.1. Selectivity 143 
Selectivity of the method was determined by analyzing six blanks of each matrix, 144 
including mobile phase, heart, kidney, liver, lung or spleen obtained from healthy mice. 145 
2.4.2. Linearity and calibration range 146 
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To evaluate linearity, calibration curves were prepared and analyzed in triplicate, 147 
comprising three independent experiments. Data were fitted to least squares linear 148 
regression concerning peak area vs. concentration for ten standards prepared in mobile 149 
phase (2, 4, 6, 8, 10, 20, 40, 60, 80 and 100 nmol L-1) or six standards prepared in each 150 
biological matrix (2, 6, 10, 20, 60 and 100 nmol L-1), and by analysis of the respective 151 
response factors (i.e., peak area divided by concentration of each standard sample). 152 
Back calculated concentrations were also obtained [20]. 153 
2.4.3. Accuracy and precision 154 
The accuracy and precision were determined by analyses of QC samples at three 155 
concentration levels (6, 20 and 100 nmol L-1). The accuracy was expressed by percent 156 
of the nominal concentration value ((mean measured concentration)/(nominal 157 
concentration) × 100%) and the precision by the coefficient of variation (standard 158 
deviation/mean) × 100%). Intra-day (within-run) values were obtained by replicate 159 
analyses (n = 6) followed by interpolation in calibration curves prepared on the same 160 
day. Inter-day (between-run) values were obtained from 3 independent experiments (n = 161 
3). 162 
2.4.4. Limit of detection and quantification 163 
The limits of detection (LOD) and quantification (LOQ) for each matrix were calculated 164 
as f × σ / S, where f is 3 (LOD) or 10 (LOQ), σ is the statistics sy/x, and S is the slope of 165 
the calibration curve [22]. 166 
2.4.5. Robustness 167 
The short-term stability was assessed by maintaining the QC samples at RT for 24 h. 168 
Freeze-thaw stability of the samples was obtained over three freeze-thaw cycles, by 169 
thawing at RT for 2 h and refreezing for 24 h. Autosampler stability of BNIPDaoct was 170 
tested by analysis of QC samples, which were stored in the autosampler tray of the 171 
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HPLC instrument for 24 h. For each concentration and each storage condition, six 172 
replicates were analyzed in one analytical batch. The concentration of BNIPDaoct after 173 
each storage period was compared to the initial concentration determined for the fresh 174 
samples, processed immediately after preparation. 175 
2.5. Recovery of BNIPDaoct from biological tissue 176 
Extractions for the recoveries of BNIPDaoct from biological matrices at three QC levels 177 
were performed by spiking the organ extract (section 2.4.2) in mobile phase or by 178 
spiking the organ tissue before extraction. Recovery and precision were determined as 179 
described in Section 2.4.3. 180 
2.6. Application to biodistribution studies 181 
Six-week-old male BALB/c mice were used (Charles River, Barcelona, Spain). Animals 182 
were housed five per cage for acclimatization one week before the experiments at the 183 
animal resource facilities of the IBMC (Porto, Portugal). All experiments were 184 
approved by and conducted in accordance with the IBMC/INEB Animal Ethics 185 
Committee and the Portuguese Veterinary Director General guidelines. Formulations 186 
containing BNIPDaoct in solution or nanoencapsulated (165 µM) were administered 187 
intravenous via the lateral tail vein (1.0 mg kg-1) to each group of four healthy male 188 
BALB/c mice. The animals were sacrificed 1 h after BNIPDaoct injection with lethal 189 
dose of anaesthesia. The organs were collected and preserved in ice during all the 190 
procedure. The concentration of BNIPDaoct in the biological matrices (spleen, heart, 191 
liver, lungs, and kidneys) was determined by processing the samples as described in 192 
section 2.3.3, with further assessment of BNIPDaoct content by the developed and 193 
validated HPLC method. 194 
 195 
 196 
9 
3. Results and discussion 197 
3.1. Development of chromatographic method 198 
Considering the method application to studies of biodistribution and pharmacokinetics, 199 
the main goal to be achieved in the development of this chromatographic method was 200 
low detection and quantification limits, using low sample volumes. Furthermore, as a 201 
high sample throughput was aimed, a monolithic column coupled to fluorescence 202 
detection was chosen to meet these needs. 203 
Moreover, the development of a simplified HPLC method with isocratic elution was 204 
aimed. Acetonitrile was chosen as organic component and the aqueous component was 205 
composed by 0.10 mol L-1 acetic acid/acetate buffer, pH 4.5 and 0.010 mol L-1 206 
octanesulfonic acid in order to guarantee pH control (buffer) and to avoid peak tailing 207 
(sulfonate as ionic pairing agent). The effect of aqueous to organic ratio was 208 
investigated using 0.05 µM BNIPDaoct standard. As expected, when the percentage of 209 
the organic phase increases, the retention time of BNIPDaoct decreases. For example, 210 
when increasing the organic phase from 35 to 50% (v/v), the retention time decreased to 211 
20.3%. In fact, for intermediate percentages of 40 and 45% (v/v), the retention time was 212 
39.2 and 25.0% of that observed for 35% (v/v) of acetonitrile. Hence, in order to attain a 213 
fast separation while maintaining good separation of BNIPDaoct from the void volume 214 
signal (non-retained matrix components), the proportion of aqueous to organic 215 
components in the mobile phase was fixed at 60:40 (v/v). 216 
Considering that monolithic columns can provide analyte separations using high flow 217 
rates with an increase of pressure that can be withstand by any HPLC system, the flow 218 
rate applied was studied, in order to maximize sample throughput and minimize mobile 219 
phase consumption. The retention time decreased to 25.7, 33.7 and 50.2% when 220 
applying 2.0, 1.5, and 1.0 mL min-1, compared to the value obtained for 0.5 mL min-1. 221 
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Hence, a flow rate of 1.5 mL min-1 was selected, considering that it afforded low 222 
acetonitrile consumption and a pressure of 2.5 MPa within the HPLC system. The run 223 
time was 6 min, with a retention time of 3.3 min for BNIPDaoct compound. 224 
3.2. Method validation and application to biological samples 225 
The validation of the analytical HPLC method was carried out by evaluating its 226 
selectivity, linearity, intra-day and inter-day precision and accuracy, stability, and 227 
extraction recovery. 228 
For selectivity, analyses of blank samples of all the matrices were performed as shown 229 
in Fig. 2, where a chromatogram for 0.10 µmol L-1 BNIPDaoct standard is also 230 
presented. No interference for BNIPDaoct detection from endogenous compounds 231 
present in tissue extracts was observed as no peaks at the BNIPDaoct retention time 232 
were detected (Fig. 2). Any potential interfering compound was washed from the 233 
column together with the solvent front, particularly for liver and kidney sample234 
 235 
Figure 2. Chromatograms of BNIPDaoct (0.10 µmol L-1, A) and blank heart (B), spleen 236 
(C), lung (D), kidney (E), and liver (F). 237 
 238 
Regression analysis data from calibration curves in mobile phase and biological tissue 239 
extracts are given in Table 1. Two calibration ranges were established for BNIPDaoct: a 240 
low range for concentrations between 0.002 and 0.020 µmol L-1 and a high range 241 
A 
B 
C 
D 
E 
F 
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between 0.010 and 0.100 µmol L-1. Sensitivity, assessed as the slope of the calibration 242 
curve, was 5 to 10% lower for the low range. Calibration curves for BNIPDaoct in 243 
mobile phase were linear and reproducible, with correlation coefficient > 0.9996. The 244 
back calculated concentrations presented deviations < 5.9% from the nominal value, 245 
meeting the requirements of EMA guideline [20]. The calculated LOD was 0.5 nmol L-1 246 
and the LOQ was 1.6 nmol L-1. 247 
Calibration curves for BNIPDaoct in the biological matrices tested were also linear for 248 
the two ranges correlation coefficients ≥ 0.9997 (Table 1). The LOD and LOQ for 249 
biological matrices were ≤ 0.8 and ≤ 1.8 nmol L-1, respectively (Table 1), corresponding 250 
to values ≤ 4 and ≤ 9 nmol g-1 in mice organs. 251 
Table 1. Calibration curve parametersa, limit of detection (LOD) and quantification 252 
(LOQ) for BNIPDaoct in mobile phase and tissue extracts. 253 
Matrix Range (µmol L-1) Slope (L µmol-1) Intercept LOD (µmol L-1) 
LOQ 
(µmol L-1) 
Mobile phase 0.002 – 0.020 4.837 × 107 7299 0.0005 0.0016 
 0.010 – 0.100 5.269 × 107 -33879 --- --- 
Spleen 0.002 – 0.020 4.932 × 107 3291 0.0003 0.0011 
 0.010 – 0.100 5.118 × 107 -15036 --- --- 
Heart 0.002 – 0.020 4.931 × 107 4488 0.0002 0.0010 
 0.010 – 0.100 5.111 × 107 -12331 --- --- 
Liver 0.002 – 0.020 4.918 × 107 -16174 0.0008 0.0018 
 0.010 – 0.100 5.307 × 107 -60002 --- --- 
Lungs 0.002 – 0.020 4.838 × 107 -494 0.0004 0.0015 
 0.010 – 0.100 5.144 × 107 -18625 --- --- 
Kidneys 0.002 – 0.020 4.778 × 107 -974 0.0005 0.0016 
 0.010 – 0.100 5.028 × 107 -17567 --- --- 
a R > 0.9996 for all calibrations. 254 
Accuracy and precision (inter- and intra-day) were also estimated. The intra-day 255 
precision and accuracy were calculated by analyzing the QC of all matrices at 256 
concentrations of 0.006, 0.020 and 0.100 µmol L-1 and the 0.020 µmol L-1 standard was 257 
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interpolated in both calibration curves (Table 2). The intra-day precision was ≤ 1.9% 258 
and accuracy ranged between 97.3 and 106.8%. The inter-day precision was ≤ 7.2% and 259 
accuracy ranged between 96.6 and 105.6% (Table 2). Both intra- and inter-day precision 260 
and accuracy found have acceptable values, because precision for each concentration 261 
level, represented as CV, did not exceed 15% and the accuracy range was between 85 262 
and 115% [20]. 263 
Table 2. Accuracy and precision for the analysis of BNIPDaoct in mobile phase and 264 
tissue extracts. 265 
  Intra-day   Inter-day   
Matrix Nominal 
concentration a 
(µmol L-1) 
Measured concentration Measured concentration 
  Mean (µmol 
L-1) 
Accuracy 
(%) 
CV (%) Mean (µmol L-
1) 
Accuracy 
(%) 
CV (%) 
Mobile 
phase 
0.006 0.0058 97.3 1.4 0.0058 96.6 5.4 
 0.020 (LL) 0.0202 101.1 0.7 0.0204 101.8 1.4 
 0.020 (HL) 0.0200 100.2 1.5 0.0199 99.9 0.6 
 0.100 0.1001 100.1 1.6 0.1001 100.1 1.0 
Spleen 0.006 0.0061 101.6 1.9 0.0061 102.0 1.7 
 0.020 (LL) 0.0199 99.7 0.5 0.0200 100.1 0.4 
 0.020 (HL) 0.0198 99.2 0.6 0.0199 99.5 0.5 
 0.100 0.1002 100.2 0.2 0.1001 100.1 0.3 
Heart 0.006 0.0060 100.7 0.7 0.0061 101.1 0.6 
 0.020 (LL) 0.0199 99.3 0.1 0.0200 100.0 0.6 
 0.020 (HL) 0.0198 99.0 0.2 0.0199 99.4 0.5 
 0.100 0.1004 100.4 0.1 0.1004 100.4 0.1 
  266 
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In order to evaluate the robustness of the developed method, stability and recovery 267 
assays were performed. The stability of BNIPDaoct at laboratory temperature was 268 
assessed analyzing fresh samples and analyzing the same samples after 24 h at RT (20 ± 269 
2 °C). BNIPDaoct showed stability in all matrices after this period as can be seen from 270 
data in Table 3, where recoveries ranged from 92.6 to 105.9%. The autosampler 271 
stability was assessed analyzing fresh samples and analyzing the same samples after 24 272 
h after the first injection. BNIPDaoct was stable in the autosampler for at least 24 h 273 
(Table 3), providing recovery values in all matrices between 94.1 and 103.2%. The 274 
freeze–thaw stability of BNIPDaoct over three freeze–thaw cycles was also assessed, 275 
providing values of 89.1-102.5% for analyte recovery (Table 3), showing the stability 276 
during sample storage and handling. 277 
Table 3. Stability of BNIPDaoct at different experimental conditions for all matrices 278 
tested. 279 
Experimental condition 24 h at room temperature 24 h in the autosampler 3 freeze-thaw cycles 
Matrix Nominal 
concentratio
na (µmol L-
1) 
Measured concentration Measured concentration Measured concentration 
Mean 
(µmol L-1) 
Accuracy 
(%) 
CV 
(%) 
Mean 
(µmol L-1) 
Accurac
y (%) 
CV 
(%) 
Mean 
(µmol L-1) 
Accurac
y (%) 
CV 
(%) 
Mobile 
phase 
0.006 0.0057 94.3 0.8 0.0053 88.5 2.1 0.0057 95.6 2.5 
 0.020 (LL) 0.0201 100.6 0.6 0.0191 95.5 1.4 0.0201 100.5 1.0 
 0.020 (HL) 0.0197 98.4 0.5 0.0193 96.7 0.5 0.0195 97.4 1.5 
 0.100 0.0993 99.3 1.3 0.0947 94.7 3.7 0.0973 97.3 0.6 
Spleen 0.006 0.0061 100.9 1.5 0.0058 96.6 2.4 0.0058 97.0 1.0 
 0.020 (LL) 0.0197 98.7 0.5 0.0195 97.5 0.4 0.0198 99.0 0.4 
 0.020 (HL) 0.0197 98.3 0.5 0.0194 97.0 0.4 0.0195 97.7 0.4 
 0.100 0.0999 99.9 0.1 0.0976 97.6 0.7 0.0979 97.9 0.1 
Heart 0.006 0.0059 98.7 0.6 0.0059 97.6 0.9 0.0058 96.4 1.4 
 0.020 (LL) 0.0199 99.3 0.3 0.0197 98.4 0.3 0.0198 99.2 0.2 
 0.020 (HL) 0.0198 99.0 0.4 0.0197 98.2 0.3 0.0197 98.6 0.1 
 0.100 0.0983 98.3 0.1 0.0983 98.3 0.1 0.0984 98.4 0.1 
  280 
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Finally, extraction efficiency was assessed, by spiking organs harvested from healthy 281 
animals and processing as described in section 2.3.3 (Table 4). Recoveries were similar 282 
to all tissues and for both BNIPDaoct in solution (mean recovery 93.2 ± 2.1%) and 283 
nanoencapsulated BNIPDaoct (mean recovery 92.3 ± 2.4%). Therefore, recovery values 284 
are acceptable for all organs and suitable for reliable bioanalysis. 285 
Table 4. Extraction efficiency of BNIPDaoct from mouse organs at different 286 
concentration levels 287 
 BNIPDaoct solution BNIPDaoct nanoparticles 
Matrix Target 
concentration 
on extract 
(µmol L-1) 
BNIPDaoct:org
an mass ratio 
Recovery 
(%) 
CV (%) BNIPDaoct:org
an mass ratio 
Recover
y (%) 
CV 
(%) 
Spleen 0.006 2.3 × 10-8 94.7 1.6 2.3 × 10-8 87.5 1.1 
 0.020 (LL) 7.8 × 10-8 93.9 0.6 7.8 × 10-8 95.1 0.2 
 0.020 (HL) 7.8 × 10-8 94.0 0.8 7.8 × 10-8 95.4 0.5 
 0.100 3.8 × 10-7 90.0 0.1 3.9 × 10-7 87.6 0.1 
Heart 0.006 2.3 × 10-8 93.3 0.8 2.4 × 10-8 96.1 1.4 
 0.020 (LL) 3.1 × 10-8 90.8 0.8 7.8 × 10-8 91.2 1.0 
 0.020 (HL) 3.1 × 10-8 90.2 0.3 7.8 × 10-8 91.3 0.8 
 0.100 1.6 × 10-7 90.6 0.2 3.9 × 10-7 89.0 0.1 
Liver 0.006 1.2 × 10-8 93.7 1.4 9.4 × 10-9 92.4 1.0 
 0.020 (LL) 3.1 × 10-8 95.3 1.4 3.1 × 10-8 93.3 0.7 
 0.020 (HL) 3.1 × 10-8 94.2 0.7 3.1 × 10-8 94.4 1.1 
 0.100 1.7 × 10-7 94.0 0.3 1.6 × 10-7 92.2 0.3 
288 
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Table 4. Extraction efficiency of BNIPDaoct from mouse organs at different 289 
concentration levels (continuation). 290 
 BNIPDaoct solution BNIPDaoct nanoparticles 
Matrix Target 
concentration on 
extract (µmol L-1) 
BNIPDaoct:organ 
mass ratio 
Recovery 
(%) 
CV (%) BNIPDaoct:organ 
mass ratio 
Recovery 
(%) 
CV 
(%) 
Lungs 0.006 9.2 × 10-9 93.4 0.9 9.4 × 10-9 91.9 1.5 
 0.020 (LL) 3.1 × 10-8 95.0 1.1 3.1 × 10-8 92.7 0.7 
 0.020 (HL) 3.1 × 10-8 95.5 0.7 3.1 × 10-8 93.1 0.8 
 0.100 1.6 × 10-7 93.2 0.2 1.6 × 10-7 92.2 0.2 
Kidneys 0.006 9.4 × 10-9 91.1 0.8 9.4 × 10-9 92.4 1.0 
 0.020 (LL) 3.1 × 10-8 92.0 0.1 3.1 × 10-8 93.3 0.7 
 0.020 (HL) 3.1 × 10-8 91.4 0.3 3.1 × 10-8 94.4 1.1 
 0.100 1.6 × 10-7 98.3 0.1 1.6 × 10-7 92.2 0.3 
 291 
3.3. Application to biodistribution assessment 292 
The validated HPLC method was applied to assess the biodistribution of free and 293 
nanoencapsulated BNIPDaoct. The amount found in each organ and the relative 294 
distribution is given in Fig. 3. A larger amount of BNIPDaoct (3.1% of administered 295 
mass as free drug) was found compared to BNIPDaoct administered in 296 
nanoencapsulated form (1.5% of administered mass). The distribution per harvested 297 
organs was similar for both formulations, with a large amount found in liver (68%), and 298 
followed by kidney (16%), spleen (10%), lung (5%) and heart (1%). Considering the 299 
organs were harvested 1 hour after drug administration, a similar distribution profile 300 
was observed, with a larger amount of free drug recovered. Nevertheless, we would 301 
expect an increased amount of encapsulated BNIPDaoct if quantification was performed 302 
following a longer time (e.g. 24 h) after drug administration because the bio-303 
16 
accumulation of encapsulated BNIPDaoct requires more time due to their interactions 304 
with complement system and inespecific cellular interactions. 305 
  306 
                                     A      B 307 
Figure 3. Amount (A) and relative distribution (B) of BNIPDaoct recovered from mice 308 
organs (n = 4) after administration of nanoencapsulated (white bars) or free drug (black 309 
bars). 310 
 311 
4. Conclusions 312 
A simple, sensitive, accurate and precise HPLC method was developed and fully 313 
validated for determination of BNIPDaoct in biological samples. This method was 314 
convenient for the quantification of BNIPDaoct in mice organ samples and it was 315 
successfully applied to the evaluation of biodistribution of BNIPDaoct in mice. Further 316 
application will target pharmacokinetic studies and application of other formulations for 317 
BNIPDaoct delivery. Furthermore this validated method can potentially be applied in 318 
the biodistribution of other mono and bisnaphthalimido molecules. 319 
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Figure Captions 398 
 399 
Figure 1. Chemical structure of bisnaphthalimidopropyldiaaminooctane (BNIPDaoct). 400 
 401 
Figure 2. Chromatograms of BNIPDaoct (0.10 µmol L-1, A) and blank heart (B), spleen 402 
(C), lung (D), kidney (E), and liver (F). 403 
 404 
Figure 3. Amount (A) and relative distribution (B) of BNIPDaoct recovered from mice 405 
organs (n = 4) after administration of nanoencapsulated (white bars) or free drug (black 406 
bars). 407 
 408 
